BioCentury | Feb 2, 2021
Product Development

U.S. solidifies goals for home COVID-19 testing via $231.8M  contract with Ellume

...is backing up the aspiration via a $231.8 million deal with rapid antigen test developer Ellume.The...
...day. As part of the agreement with the U.S. Department of Defense (DOD) and HHS, Ellume...
...COVID-19 Response and Pandemic Preparedness.While other COVID-19 tests received emergency use authorization (EUA) from FDA, Ellume Ltd.’s...
BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

...COVID-19 antigen test. Developed by Australian biotech Ellume Ltd....
...is an order of magnitude larger than Ellume’s. Like...
...be used to facilitate access to in-person venues.Ellume...
BioCentury | Dec 17, 2020
Regulation

As first OTC COVID-19 test raises stakes for consumer guidance, Abbott opts for prescription path

...uncertainty around results.  Abbott’s home test, authorized Wednesday, brings a narrower indication but higher volume.Brisbane-based Ellume Ltd....
...administer 30 million at-home tests in 1Q21 and another 90 million in 2Q21; in contrast, Ellume...
...communicate the possibility of false positives and negatives, a step FDA took when it announced Ellume’s...
BioCentury | Dec 11, 2020
Product Development

Strides forward for COVID-19 screening as FDA authorizes first consumer home collection kit, with OTC rapid test in the pipeline

...from a healthcare provider, while negative results are communicated electronically.The same day, Brisbane-based diagnostics company Ellume...
...a miniaturized version of the technology used in the point-of-care immunoassay instrument from Quidel Corp. (NASDAQ:QDEL), Ellume...
...Parsons told BioCentury. He said that in terms of scalability and control of interpretation of results, Ellume’s...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

...enough antibodies to start Phase I testing.Qiagen, Ellume...
...QIAreach SARS-CoV-2 Antigen Test, developed in partnership with Ellume...
...Research Institute of Epidemiology and Microbiology Pfizer Inc. BioNTech SE Ellume Qiagen...
BioCentury | Oct 8, 2020
Finance

Data Bytes: RADx funding recipients

...easy-to-use COVID-19 tests.The most recent contracts, issued via RADx’s third round of funding, were awarded to Ellume...
BioCentury | Oct 7, 2020
Product Development

Antigen tests outshine PCR at predicting who can transmit SARS-CoV-2

...in manufacturing expansion contracts.The contracts were awarded to Ellume...
Items per page:
1 - 7 of 7
BioCentury | Feb 2, 2021
Product Development

U.S. solidifies goals for home COVID-19 testing via $231.8M  contract with Ellume

...is backing up the aspiration via a $231.8 million deal with rapid antigen test developer Ellume.The...
...day. As part of the agreement with the U.S. Department of Defense (DOD) and HHS, Ellume...
...COVID-19 Response and Pandemic Preparedness.While other COVID-19 tests received emergency use authorization (EUA) from FDA, Ellume Ltd.’s...
BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

...COVID-19 antigen test. Developed by Australian biotech Ellume Ltd....
...is an order of magnitude larger than Ellume’s. Like...
...be used to facilitate access to in-person venues.Ellume...
BioCentury | Dec 17, 2020
Regulation

As first OTC COVID-19 test raises stakes for consumer guidance, Abbott opts for prescription path

...uncertainty around results.  Abbott’s home test, authorized Wednesday, brings a narrower indication but higher volume.Brisbane-based Ellume Ltd....
...administer 30 million at-home tests in 1Q21 and another 90 million in 2Q21; in contrast, Ellume...
...communicate the possibility of false positives and negatives, a step FDA took when it announced Ellume’s...
BioCentury | Dec 11, 2020
Product Development

Strides forward for COVID-19 screening as FDA authorizes first consumer home collection kit, with OTC rapid test in the pipeline

...from a healthcare provider, while negative results are communicated electronically.The same day, Brisbane-based diagnostics company Ellume...
...a miniaturized version of the technology used in the point-of-care immunoassay instrument from Quidel Corp. (NASDAQ:QDEL), Ellume...
...Parsons told BioCentury. He said that in terms of scalability and control of interpretation of results, Ellume’s...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

...enough antibodies to start Phase I testing.Qiagen, Ellume...
...QIAreach SARS-CoV-2 Antigen Test, developed in partnership with Ellume...
...Research Institute of Epidemiology and Microbiology Pfizer Inc. BioNTech SE Ellume Qiagen...
BioCentury | Oct 8, 2020
Finance

Data Bytes: RADx funding recipients

...easy-to-use COVID-19 tests.The most recent contracts, issued via RADx’s third round of funding, were awarded to Ellume...
BioCentury | Oct 7, 2020
Product Development

Antigen tests outshine PCR at predicting who can transmit SARS-CoV-2

...in manufacturing expansion contracts.The contracts were awarded to Ellume...
Items per page:
1 - 7 of 7